PriceTargets.com logo

Surgery Partners - SGRY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.36
  • Forecasted Upside: 93.89%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$12.05 As of 03/19/2026 05:00 PM ET
▼ -0.31 (-2.51%)

This chart shows the closing price for SGRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Surgery Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGRY

Analyst Price Target is $23.36
▲ +93.89% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Surgery Partners in the last 3 months. The average price target is $23.36, with a high forecast of $36.00 and a low forecast of $14.00. The average price target represents a 93.89% upside from the last price of $12.05.

This chart shows the closing price for SGRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Surgery Partners. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2026UBS GroupReiterated RatingBuy ➝ Buy
3/11/2026US Capital AdvisorsSet Target$21.00
3/5/2026TD CowenLower TargetBuy ➝ Buy$28.00 ➝ $20.00
3/5/2026UBS GroupLower TargetBuy ➝ Buy$29.00 ➝ $21.00
3/5/2026MizuhoLower TargetOutperform ➝ Outperform$19.00 ➝ $17.00
3/4/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy
3/4/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
3/4/2026Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$31.00 ➝ $20.00
3/3/2026Jefferies Financial GroupSet Target$30.00
3/3/2026BenchmarkReiterated RatingBuy ➝ Buy
3/3/2026BarclaysLower TargetEqual Weight ➝ Equal Weight$18.00 ➝ $14.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/18/2025MizuhoLower TargetOutperform ➝ Outperform$22.00 ➝ $19.00
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$27.00 ➝ $20.00
11/21/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$24.00 ➝ $18.00
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025MizuhoLower TargetOutperform ➝ Outperform$28.00 ➝ $22.00
11/13/2025UBS GroupLower TargetBuy ➝ Buy$34.00 ➝ $29.00
11/11/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$35.00 ➝ $31.00
11/11/2025BenchmarkLower TargetBuy ➝ Buy$35.00 ➝ $30.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/7/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$36.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/18/2025JPMorgan Chase & Co.Initiated CoverageNeutral$27.00
7/28/2025Bank of AmericaInitiated CoverageBuy$28.00
5/27/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$25.00 ➝ $24.00
4/21/2025BenchmarkReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/25/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
3/11/2025Macquarie InfrastructureLower TargetOutperform ➝ Outperform$34.00 ➝ $33.00
12/16/2024Bank of AmericaInitiated CoverageBuy$30.00
12/3/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$38.00 ➝ $28.00
11/20/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$49.00 ➝ $35.00
11/19/2024Macquarie InfrastructureReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
11/13/2024Macquarie InfrastructureLower TargetOutperform ➝ Outperform$35.00 ➝ $34.00
11/4/2024Macquarie InfrastructureReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
10/14/2024UBS GroupInitiated CoverageBuy$38.00
10/11/2024KeyCorpInitiated CoverageSector Weight
10/4/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00 ➝ $43.00
8/26/2024BenchmarkReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00 ➝ $43.00
8/7/2024BenchmarkReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/7/2024CitigroupLower TargetBuy ➝ Buy$38.00 ➝ $36.00
8/7/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$49.00 ➝ $49.00
7/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00 ➝ $43.00
7/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00 ➝ $43.00
6/28/2024Macquarie InfrastructureInitiated CoverageOutperform$31.00
5/8/2024CitigroupLower TargetBuy ➝ Buy$42.00 ➝ $38.00
5/1/2024BenchmarkReiterated RatingBuy ➝ Buy$50.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00
3/6/2024BarclaysInitiated CoverageEqual Weight$35.00
3/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00
2/29/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$49.00
2/27/2024CitigroupLower TargetBuy ➝ Buy$43.00 ➝ $42.00
2/27/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00
11/14/2023TD CowenUpgradeMarket Perform ➝ Outperform$39.00 ➝ $35.00
10/12/2023BenchmarkReiterated RatingBuy ➝ Buy$50.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$43.00
8/2/2023BenchmarkReiterated RatingBuy ➝ Buy$50.00
8/2/2023BarclaysLower TargetOverweight ➝ Overweight$56.00 ➝ $51.00
7/11/2023MizuhoBoost Target$48.00 ➝ $50.00
6/2/2023Bank of AmericaUpgradeNeutral ➝ Buy$42.00 ➝ $45.00
5/12/2023MizuhoInitiated CoverageBuy$48.00
5/2/2023CitigroupBoost Target$40.00 ➝ $47.00
4/20/2023Cantor FitzgeraldInitiated CoverageOverweight$43.00
3/6/2023BenchmarkReiterated RatingBuy$47.00
3/2/2023JPMorgan Chase & Co.Lower TargetNeutral$45.00 ➝ $40.00
3/2/2023CitigroupBoost Target$38.00 ➝ $40.00
1/18/2023BarclaysLower TargetOverweight$69.00 ➝ $56.00
12/5/2022BenchmarkLower TargetBuy$60.00 ➝ $47.00
11/23/2022Royal Bank Of CanadaLower TargetOutperform$58.00 ➝ $48.00
11/23/2022JPMorgan Chase & Co.Lower Target$57.00 ➝ $45.00
11/22/2022Stifel NicolausLower Target$44.00 ➝ $36.00
11/22/2022Leerink PartnersLower TargetOutperform$55.00 ➝ $40.00
11/16/2022TD CowenLower Target$35.00
11/10/2022Royal Bank Of CanadaLower TargetOutperform$62.00 ➝ $58.00
11/10/2022Leerink PartnersLower TargetOutperform$57.00 ➝ $55.00
11/9/2022CitigroupLower TargetBuy$49.00 ➝ $38.00
8/9/2022TD CowenLower Target$39.00
8/3/2022Royal Bank Of CanadaLower TargetOutperform$65.00 ➝ $62.00
6/15/2022Bank of AmericaDowngradeBuy ➝ Neutral$55.00 ➝ $36.00
5/4/2022BenchmarkBoost Target$65.00 ➝ $72.00
5/4/2022CitigroupBoost Target$61.00 ➝ $64.00
3/2/2022JPMorgan Chase & Co.Boost TargetNeutral$50.00 ➝ $55.00
3/2/2022Leerink PartnersBoost TargetOutperform$63.00 ➝ $65.00
3/1/2022Royal Bank Of CanadaLower TargetOutperform$70.00 ➝ $65.00
1/26/2022Leerink PartnersBoost TargetOutperform$61.00 ➝ $63.00
12/3/2021Leerink PartnersBoost TargetOutperform$52.00 ➝ $61.00
11/30/2021BarclaysInitiated CoverageOverweight$73.00
11/29/2021Stifel NicolausUpgradeHold ➝ Buy$51.00
11/3/2021Leerink PartnersBoost TargetOutperform$50.00 ➝ $52.00
11/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$50.00
10/18/2021Leerink PartnersInitiated CoverageOutperform$50.00
9/9/2021TD CowenInitiated CoverageMarket Perform$50.00
6/22/2021Stifel NicolausInitiated CoverageHold
5/6/2021Royal Bank Of CanadaBoost TargetOutperform$54.00 ➝ $61.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 2 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 25 very positive mentions
  • 27 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 25 very positive mentions
  • 27 positive mentions
  • 6 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Surgery Partners logo
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Read More

Today's Range

Now: $12.05
Low: $11.61
High: $12.46

50 Day Range

MA: $14.69
Low: $12.05
High: $16.28

52 Week Range

Now: $12.05
Low: $11.61
High: $24.60

Volume

1,866,858 shs

Average Volume

1,747,090 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Surgery Partners?

The following sell-side analysts have issued reports on Surgery Partners in the last year: Bank of America Corporation, Barclays PLC, Benchmark Co., Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Royal Bank Of Canada, TD Cowen, UBS Group AG, US Capital Advisors, and Weiss Ratings.
View the latest analyst ratings for SGRY.

What is the current price target for Surgery Partners?

0 Wall Street analysts have set twelve-month price targets for Surgery Partners in the last year. Their average twelve-month price target is $23.36, suggesting a possible upside of 93.9%. Cantor Fitzgerald has the highest price target set, predicting SGRY will reach $36.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $14.00 for Surgery Partners in the next year.
View the latest price targets for SGRY.

What is the current consensus analyst rating for Surgery Partners?

Surgery Partners currently has 1 sell rating, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SGRY.

What other companies compete with Surgery Partners?

Other companies that are similar to Surgery Partners include Tenet Healthcare, Hims & Hers Health, PACS Group, Celcuity and Caris Life Sciences. Learn More about companies similar to Surgery Partners.

How do I contact Surgery Partners' investor relations team?

Surgery Partners' physical mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company's listed phone number is (615) 234-5900 and its investor relations email address is [email protected]. The official website for Surgery Partners is www.surgerypartners.com. Learn More about contacing Surgery Partners investor relations.